Literature DB >> 4089101

Measurement of side effects including tardive dyskinesia.

M Campbell, M Palij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4089101

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


× No keyword cloud information.
  9 in total

1.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

2.  Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia.

Authors:  Lauren I Kasoff; Kwangmi Ahn; Peter Gochman; Diane D Broadnax; Judith L Rapoport
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-01-19       Impact factor: 2.576

3.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

4.  Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function.

Authors:  S Dollfus; M Petit; J F Menard; P Lesieur
Journal:  J Autism Dev Disord       Date:  1992-03

5.  Once daily risperidone in treatment of schizophrenia.

Authors:  V Agarwal; R K Chadda
Journal:  Indian J Psychiatry       Date:  2001-01       Impact factor: 1.759

6.  A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders.

Authors:  Vivek Agarwal; Prabhat Sitholey
Journal:  Indian J Psychiatry       Date:  2006-01       Impact factor: 1.759

7.  Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine.

Authors:  V Agarwal; K M Agarwal
Journal:  Indian J Psychiatry       Date:  2000-07       Impact factor: 1.759

8.  Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

Authors:  Fabio P S Santos; Bartlomiej Getta; Lucia Masarova; Christopher Famulare; Jessica Schulman; Tarcila S Datoguia; Renato D Puga; Raquel de Melo Alves Paiva; Maria E Arcila; Nelson Hamerschlak; Hagop M Kantarjian; Ross L Levine; Paulo Vidal Campregher; Raajit K Rampal; Srdan Verstovsek
Journal:  Leukemia       Date:  2019-10-18       Impact factor: 11.528

9.  An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder.

Authors:  Avinash Desousa
Journal:  Indian J Psychol Med       Date:  2010-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.